Patents by Inventor Howard Grey

Howard Grey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10703784
    Abstract: The present invention relates to M. tuberculosis proteins and peptides, and subsequences, portions or modifications thereof and methods and compounds comprising the same for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-M. tuberculosis immune response in a subject.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: July 7, 2020
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Alessandro Sette, Cecilia Arlehamm, Bjoern Peters, Howard Grey, John Sidney
  • Patent number: 10428124
    Abstract: The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologs, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 1, 2019
    Assignee: La Jolla Institute For Allergy And Immunology
    Inventors: Alessandro Sette, Veronique Schulten, Howard Grey, Bjoern Peters, Jason Greenbaum
  • Publication number: 20180078637
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 22, 2018
    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Publication number: 20150023992
    Abstract: The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 22, 2015
    Inventors: Alessandro Sette, Veronique Schulten, Howard Grey, Bjoern Peters, Jason Greenbaum
  • Publication number: 20150004189
    Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 1, 2015
    Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
  • Publication number: 20100068228
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Application
    Filed: August 5, 2009
    Publication date: March 18, 2010
    Applicant: Pharmexa Inc.
    Inventors: Alessandro SETTE, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
  • Patent number: 7611713
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: November 3, 2009
    Assignee: Pharmexa Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
  • Publication number: 20070059799
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Application
    Filed: September 18, 2006
    Publication date: March 15, 2007
    Applicant: Pharmexa Inc.
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
  • Publication number: 20070055049
    Abstract: The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.
    Type: Application
    Filed: April 6, 2004
    Publication date: March 8, 2007
    Inventors: Howard Grey, Alessandro Sette, John Sidney, Scott Southwood, Ralph Kubo, Esteban Celis, Robert Chesnut, W. Kast
  • Publication number: 20070053922
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
    Type: Application
    Filed: December 11, 2000
    Publication date: March 8, 2007
    Inventors: Alessandro Sette, John Sidney, Scott South Wood, Robert Chestnut, Esteban Celis, Howard Grey
  • Publication number: 20050271676
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human immunodeficiency virus (HIV) epitopes, and to develop epitope-based vaccines directed towards HIV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HIV infection.
    Type: Application
    Filed: January 28, 2005
    Publication date: December 8, 2005
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Brian Livingston, Robert Chesnut, Denise Baker, Esteban Celis, Ralph Kubo, Howard Grey
  • Publication number: 20050063983
    Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
    Type: Application
    Filed: September 4, 2003
    Publication date: March 24, 2005
    Inventors: Alessandro Sette, John Sidney, Scott Southwood, Maria Vitiello, Brian Livingston, Esteban Celis, Ralph Kubo, Howard Grey, Robert Chesnut
  • Publication number: 20050049197
    Abstract: This invention provides HLA-DR binding peptides, called “pan DR binding peptides” that are recognized by a broad spectrum of DR molecules. In particular, the present invention provides compositions comprising nucleic acid segments that encode such pan DR binding peptides, which are useful for enhancing the immune response to a desired immunogen.
    Type: Application
    Filed: October 7, 2004
    Publication date: March 3, 2005
    Applicant: Epimmune Inc.
    Inventors: Alessandro Sette, Federico Gaeta, Howard Grey, John Sidney, Jeffery Alexander
  • Publication number: 20030099634
    Abstract: Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.
    Type: Application
    Filed: April 22, 2002
    Publication date: May 29, 2003
    Inventors: Maria A. Vitiello, Robert W. Chesnut, Alessandro D. Sette, Esteban Celis, Howard Grey
  • Patent number: 6419931
    Abstract: Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: July 16, 2002
    Assignee: Epimmune Inc.
    Inventors: Maria A. Vitiello, Robert W. Chestnut, Alessandro D. Sette, Esteban Celis, Howard Grey
  • Patent number: 5110746
    Abstract: Serum is reacted with a dinitrohalobenzene compound and the rate of halogen formation is measured. This rate is in proportion to the amount of albumin in the sample. Other proteins like the globulins, as well as free aminoacids and urea, do not interfere with this reaction.
    Type: Grant
    Filed: December 22, 1988
    Date of Patent: May 5, 1992
    Assignee: Pharmacia Diagnostics Inc.
    Inventors: Howard Grey, Ciaran Mangan, Jean Brochot, Iqbal Siddiqi